Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Continuity Biosciences

continuitybiosciences.com ↗ · Southeast

Clinical Phase 1

Keywords: oncology drug delivery pancreatic cancer Pancreatic Adenocarcinoma Non-resectable

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

Mar 11, 2026 Trial start Phase 1: A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer source ↗

Upcoming milestones

Aug 1, 2027 (ESTIMATED) · Phase 1 · A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer · NCT07481383

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07481383	A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer	Phase 1	Recruiting	Mar 11, 2026	Aug 1, 2027 (estimated)